BPC-157 is an investigational synthetic peptide, not FDA-approved for any medical use, and it is not legally available from U.S. 503A compounding pharmacies under current FDA policy. Online “research use” products may vary in purity, sterility, and labeling. Chia does not prescribe or sell BPC-157; speak with a licensed clinician before using any peptide.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy BPC-157 peptide online?
Yes, BPC-157 is easy to find online, but that does not mean it is appropriate or verified for human use. Many products are sold as “research use only,” which usually means they are not labeled, reviewed, or dispensed as human medications.
The core issue is not whether a website can list a peptide. It is whether the product is made for patient use, reviewed by a licensed clinician, and dispensed through a lawful medical channel. For BPC-157, the answer in the U.S. is currently no for routine 503A compounding, and human efficacy data remain limited 1 2.
What online sellers usually mean by “research use only”
“Research use only” usually means the seller is describing a chemical for laboratory research, not a medication for a person. It may come as lyophilized powder, capsules, or blends, but the phrase does not prove safety, sterility, identity, or a lawful patient-prescription path.
Why “available online” does not mean appropriate for human use
Human medications require more than a label and a checkout page. They need quality controls, clinician oversight, and a reasoned risk-benefit decision. BPC-157 has been studied for tendon injury, ligament injury, muscle injury, and gut-related biology mainly in preclinical models, not in large controlled human trials 1 2.
What is BPC-157?
BPC-157 stands for body protection compound-157. It is also called gastric pentadecapeptide, synthetic pentadecapeptide, bepecin, PL 14736, PLD-116, and PL-10 in research and vendor listings.
BPC-157 is a 15-amino-acid peptide related to a sequence originally described from gastric juice. Reviews describe it as a synthetic peptide investigated for gastric mucosal integrity, soft-tissue repair, inflammation pathways, and blood-vessel signaling, mostly in animal and cell studies 1 2.
BPC-157, body protection compound-157, and gastric pentadecapeptide
A pentadecapeptide is a peptide made of 15 amino acids. In BPC-157 research, the peptide is often discussed in relation to stress response, tissue injury models, gut mucosal protection, tendon healing models, and nitric oxide signaling 1.
Synthetic peptide forms: BPC-157 free base and BPC-157 acetate
Online listings may describe BPC-157 free base or BPC-157 acetate. Those names refer to chemical forms, not proof that a product is safe, sterile, legal for patient use, or clinically effective in humans.
How BPC-157 differs from FDA-approved peptide medicines
Some peptide-based medicines are FDA-approved for specific uses, but BPC-157 is different: it has no FDA-approved indication, dosing label, route, safety warnings, or patient population. That is why it should not be treated like an approved prescription peptide 3.
Is BPC-157 FDA-approved or legal through compounding pharmacies?
BPC-157 is not FDA-approved for any medical use. Under current FDA policy, BPC-157 has been treated as a 503A Category 2 bulk drug substance, meaning it raises significant safety concerns for traditional pharmacy compounding 4.
FDA approval status for human medical use
USADA states that BPC-157 is not approved for human clinical use by the FDA or any other global health authority. It also notes that no human clinical trials establish efficacy for BPC-157 for diagnosis or treatment 3.
FDA 503A Category 2 status and why it matters
The FDA’s 503A bulk-drug framework matters because state-licensed 503A pharmacies may compound only within federal and state rules. Category 2 substances are those the FDA has identified as presenting significant safety risks for compounding under section 503A 4.
Why a licensed U.S. compounding pharmacy is different from an online research-chemical vendor
A state-licensed 503A compounding pharmacy makes medication for a specific patient after a valid prescription. A research-chemical vendor may sell a product without clinician evaluation, prescription oversight, human-use labeling, or patient follow-up.
What does BPC-157 do to heal, according to research?
The honest answer: BPC-157 has interesting preclinical healing signals, but they do not prove human benefit. The strongest signals come from animal and cell studies of tendons, ligaments, muscle, bone, nerves, and gut tissue 1 2.
What animal and cell studies suggest about tendons, ligaments, muscle, and gut tissue
A 2025 systematic review in orthopedic sports medicine found 36 eligible studies, including 35 preclinical studies and 1 clinical study. In animal models, BPC-157 was linked with better functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries, but the authors noted a lack of human clinical safety data 1.
Proposed mechanisms: angiogenesis, nitric oxide signaling, VEGFR2/Akt-eNOS, fibroblast activity, and inflammatory cytokines
Reviews describe several proposed mechanisms: angiogenesis, VEGFR2 signaling, the Akt-eNOS pathway, nitric oxide signaling, fibroblast activity, growth hormone receptor expression, ERK1/2 signaling, and changes in inflammatory cytokines. These pathways are biologically plausible, but most evidence is still preclinical 1 2.
Why preclinical healing signals do not prove human benefit
Animal studies can help explain possible mechanisms, but they cannot prove that a peptide heals a human tendon, ligament, or muscle injury. Human outcomes depend on diagnosis, injury age, load management, rehab, other health conditions, and product quality.
What has human research found about BPC-157?
Human research on BPC-157 is very limited. A 2025 scoping review described only three pilot human studies, including intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics, with no large rigorous trials 2.
The limited human evidence base
The available human reports are not enough to establish proven benefit, best route, ideal patient selection, or long-term safety. They are useful for forming research questions, not for confirming that BPC-157 works for common injuries.
Why uncontrolled case series and pilot studies cannot establish efficacy
Uncontrolled studies can be misleading because pain and function often change over time, especially with rest, physical therapy, injections, surgery, or changes in training. Without a control group, it is hard to know whether BPC-157 caused the change.
What is still unknown about dose, route, long-term safety, and patient selection
There is no FDA-labeled BPC-157 dose, route, duration, contraindication list, pregnancy warning, drug-interaction list, or long-term safety plan. That matters because many online products are used by people with injuries, chronic pain, autoimmune disease, urinary symptoms, or sports-performance goals.
What are the safety risks of buying BPC-157 online?
The main risk is that online BPC-157 is not a verified prescription medication for human use. Safety concerns include unknown human effects, contamination, impurities, sterility problems, labeling errors, and self-injection mistakes.
Unknown human safety profile
Because BPC-157 has not been extensively studied in humans, USADA warns that adverse health effects are unknown. The orthopedic systematic review also concluded that human clinical safety data are lacking 1 3.
Contamination, impurities, sterility, and dosing uncertainty
A certificate of analysis may list identity or purity for one batch, but it does not replace full medication oversight. It may not prove sterility, endotoxin control, stability after shipping, correct reconstitution, safe excipients, or that every vial matches the tested sample.
Risks of self-injection or using a product not intended for human use
Self-injection can cause infection, bleeding, dosing errors, local reactions, and delayed care for an injury that needs diagnosis. The risk is higher when the product is not dispensed as a human medication and the person is guessing how to prepare or use it.
When to talk with a licensed clinician instead of self-treating pain or injury
Talk with a clinician if you have new swelling, weakness, numbness, severe pain, fever, a suspected tendon rupture, a joint that gives way, blood in the urine, pelvic pain, or symptoms that do not improve. BPC-157 marketing should not replace a diagnosis.
How do online BPC-157 options compare?
Online BPC-157 options differ most in oversight, not branding. The safest axis to think about is licensed medical care versus unlicensed or non-prescription products.
| Option | What it usually is | Clinician review | Human-use medication standards | Key risk |
|---|---|---|---|---|
| Research-chemical vendor | Powder, vial, capsule, or blend labeled for research use | Usually no | Not the same as a patient prescription | Purity, sterility, labeling, and self-use uncertainty |
| Supplement-style product | Capsule or wellness product with broad structure/function language | Usually no | Not FDA-approved as a drug for disease treatment | Human benefit and long-term safety are not established |
| Licensed medical care | Evaluation, diagnosis, and evidence-based plan with follow-up | Yes | Uses lawful prescription channels when medication is appropriate | May not include BPC-157 because it is investigational and not in Chia’s catalog |
What certificates of analysis can and cannot prove
A certificate of analysis can be useful, but it has limits. It may show a result for a tested sample, but it does not prove that a product is appropriate for injection, safe for a specific person, legal for medical use, or effective for an injury.
Why Chia does not recommend or facilitate BPC-157 purchases
At Chia, we do not prescribe, sell, or facilitate BPC-157. The reason is simple: it is not in our live treatment catalog, it is not FDA-approved for any medical use, and the human evidence base is too limited to treat it like a proven medical therapy.
Is BPC-157 banned for athletes?
Yes. BPC-157 is prohibited in sport under the World Anti-Doping Agency’s S0 Non-Approved Substances category, according to USADA 3 7.
WADA S0 Non-Approved Substances category
The S0 category covers substances not approved for human therapeutic use by a government health authority. USADA states that BPC-157 falls in this category and is prohibited at all times 3.
USADA warnings and therapeutic use exemption considerations
Athletes should not assume that online availability or a wellness label makes a peptide allowed. If you compete, check WADA, USADA, your league, your federation, and therapeutic use exemption rules before using any peptide.
Why athletes should check sport-specific rules before using any peptide
Sport rules can be stricter than general consumer rules. They may also apply to substances in blends, contaminated products, or products with unclear labels.
Does Chia offer BPC-157 or other peptide treatments?
Chia does not offer BPC-157. We do offer certain peptide and longevity treatments in our live catalog after an online health questionnaire and licensed-provider review, with prescriptions only when clinically appropriate.
Chia does not prescribe, sell, or facilitate BPC-157
If your goal is injury recovery, chronic pain support, or sports performance, we will not route you to BPC-157. We recommend starting with a real diagnosis and an evidence-based care plan, then discussing risks and options with a licensed clinician.
Peptide and longevity treatments Chia does offer after clinician review
Chia’s current peptide and longevity catalog includes Sermorelin, NAD+, Glutathione, and GHK-Cu, plus the Foundation Longevity protocol. These are not substitutes for BPC-157, and each has its own evidence limits, risks, eligibility criteria, and form options.
| Chia treatment | Forms listed in Chia catalog | Current starting price | How access works |
|---|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Injection and nasal spray from $179/mo | Online questionnaire, licensed-provider review, prescription only if appropriate |
| NAD+ | Injection, nasal spray | Injection from $179/mo; nasal spray from $119/mo | Compounded by state-licensed 503A pharmacies and shipped to the door |
| Glutathione | Injection, nasal spray | Injection and nasal spray from $179/mo | Provider-guided plan with patient-portal messaging |
| GHK-Cu | Cream | From $159/mo | Clinician-reviewed access when appropriate |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | From $399/mo | Multi-treatment protocol after licensed-provider review |
How Chia’s online evaluation works: questionnaire, licensed provider review, eligibility, and prescription only when appropriate
Chia is 100% online. You complete a short health questionnaire, a licensed U.S. provider reviews it, and medication is prescribed only when clinically appropriate. If prescribed, treatment is compounded in the U.S. by state-licensed 503A pharmacies and shipped to your door. A prescription is never guaranteed, and compounded medications are not FDA-approved.
If you want to discuss your goals with our care team, you can start with the eligibility quiz. The visit is for clinician review, not a request for BPC-157.
What should you do if you are considering BPC-157 for pain, injury, or recovery?
Start with the problem, not the peptide. Pain or injury that lasts more than a short time deserves a diagnosis, a plan, and follow-up before you consider any investigational product.
Start with a diagnosis and evidence-based care plan
A tendon injury, ligament injury, muscle strain, urinary pain syndrome, or gut complaint may need imaging, labs, physical therapy, load changes, medication review, or referral. Using BPC-157 first can delay care that is better supported by evidence.
Questions to ask a clinician about risks, alternatives, and sports rules
- What diagnosis best explains my symptoms?
- What treatments have the strongest human evidence for my condition?
- Could any medication, supplement, or peptide interact with my health history or prescriptions?
- If I compete in sport, could this product create an anti-doping risk?
- What warning signs mean I should seek urgent care?
How to evaluate claims without relying on vendor marketing
Look for human randomized trials, clear safety data, transparent adverse-event reporting, and a lawful prescription pathway. Be careful with claims based mainly on rodent tendon models, testimonials, before-and-after stories, or “doctor recommended” language without published human data.
FAQ
You may find BPC-157 listed online, often as a research chemical, but that does not make it a verified medication for human use. It is not FDA-approved, and Chia does not prescribe, sell, or facilitate it.
No. BPC-157 is not FDA-approved for any medical use. There is no FDA-labeled dose, route, indication, contraindication list, or long-term safety plan.
Under current FDA policy, BPC-157 has been treated as a 503A Category 2 bulk drug substance because of significant safety concerns. A 2026 PCAC vote recommended inclusion on the 503A Bulks List, but that vote is advisory and the FDA’s final determination is pending.
Human proof is not established. Most supportive data come from animal and cell studies. Limited human reports exist, but large controlled trials are lacking.
Capsules avoid injection-site risks, but they do not solve the main concerns: BPC-157 is investigational, not FDA-approved, and human safety and efficacy data are limited.
The human side-effect profile is not well defined because BPC-157 has not been extensively studied in humans. Online products also add risks from contamination, impurities, sterility problems, and labeling errors.
Yes. USADA states that BPC-157 is prohibited under WADA’s S0 Non-Approved Substances category. Athletes should check WADA, USADA, league, federation, and sport-specific rules before using any peptide.
No. Chia does not prescribe, sell, or facilitate BPC-157. Chia does offer certain peptide and longevity treatments, including Sermorelin, NAD+, Glutathione, and GHK-Cu, after licensed-provider review when clinically appropriate.
References
- 1.Vasireddi R, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. HSS Journal. 2025.
- 2.Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. 2025.
- 3.United States Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes. 2024.
- 4.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. 2026.
- 5.U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting. 2026.
- 6.FDA Law Blog. PCAC Recommends Six of Seven Peptides for the 503A Bulks List; FDA Final Decisions Pending. 2026.
- 7.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. 2026.
- 8.National Center for Biotechnology Information. PubChem Compound Summary for BPC-157. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
